Innovative Targeting Solutions Inc. (InnoTarg) is focused on the development of novel human antibody technologies.

InnoTarg felt that there was room for improvement in the antibody generation process given that many technologies rely on the isolation of antibodies that have been subject to negative selection which results in a large set of antibody specificities being deleted and subsequently absent from these antibody repertoires.

This is an inherent limitation of in vivo derived antibodies that InnoTarg's HuTARG technology overcomes allowing access to antibodies not possible by any other current technology. In addition, unlike antibodies derived from in vivo sources which contain somatic hypermutation events that result in divergence away from the native sequences found in the genome, the antibodies generated by InnoTarg's technology are preconfigured to be completely germline except in CDR's.

This advancement makes the fully human HuTARG antibodies the most "human" of all fully human antibody technologies and decreases the likelihood of immunogenicity and completely eliminates the need for antibodies to be "germlined" prior to development as a human therapeutic. InnoTarg believes it has developed the next paradigm for fully human antibody generation and is currently seeking strategic partners looking for early access to this new technology